Table 1.
Baseline characteristics
| All (n = 24) | SVRs (n=6) | NRs (n=18) | P value | |
|---|---|---|---|---|
| Male: Female, n | 21:3 | 6:0 | 15:3 | 0.54 |
| Median age in years, (IQR) | 46.5 (42.5-48.5) | 47.0 (37.0-55.0) | 46.5 (43.0-48.0) | 0.64 |
| Race, n (%) | ||||
| Caucasian | 7 (29) | 3 (50) | 4 (22) | 0.48 |
| African American | 12 (50) | 2 (33) | 10 (56) | |
| Hispanic | 5 (21) | 1 (17) | 4 (22) | |
| Median weight in kilograms, (IQR)* | 83.0 (78.5-88.5) | 81.6 (65.8-82.6) | 84.6 (79.8-89.8) | 0.04 |
| Median body mass index (kg/m2), (IQR) | 25.5 (23.5-29.0) | 24.3 (22.2-25.2) | 26.7 (23.6-30.0) | 0.10 |
| Median CD4 (cells/mm3), (IQR) | 467.0 (326.5-502.0) | 361.5 (209.0-493.0) | 477.5 (434.0-506.0) | 0.13 |
| Patients with plasma HIV RNA <400 copies/ml, (%) | 16 (67) | 5 (83) | 11 (61) | 0.62 |
| Median serum HCV RNA (log10 IU/ml)*, (IQR) | 6.3 (5.4 -6.7) | 5.3 (4.7-5.5) | 6.6 (6.1-6.8) | 0.003 |
| HCV genotype, (%) | ||||
| HCV 1a/b | 21 (87.5) | 5 (83) | 16 (89) | 1.0 |
| HCV 2 or 3a | 3 (12.5) | 1 (17) | 2 (11) | |
| Median hemoglobin level (g/dl), (IQR) | 13.5 (12.5-15.0) | 14.5 (13.3-15.3) | 13.1 (12.4-14.5) | 0.20 |
| Median ALT (U/l), (range) | 85.5 (40.0 - 119.0) | 203.0 (34.0 - 299.0) | 65.0 (42.0 - 113.0) | 0.14 |
| Inflammatory grade, n (%) | ||||
| 0 - 2 | 14 (58) | 3 (50) | 11 (61) | 0.67 |
| 3 - 4 | 10 (42) | 3 (50) | 7 (39) | |
| Fibrosis stage, n (%) | ||||
| 0 - 2 | 11 (46) | 2 (33) | 9 (50) | 0.65 |
| 3 - 4 | 13 (54) | 4 (67) | 9 (50) |
Abbreviations: SVRs, sustained virological responders; NRs, nonresponders; IQR, interquartile range; IU, international units; ALT, alanine aminotransferase; HCV, hepatitis C virus; HIV, human immunodeficiency virus.
*
p<0.05 for a difference between SVRs and NRs